Back

prof. dr. M.J.M. (Marc ) Bonten

prof. dr. M.J.M. (Marc ) Bonten

Full Professor
prof. dr. M.J.M. (Marc ) Bonten
  • Department of Epidemiology
  • Julius Center Research Program Infectious Diseases

Research Programs

Infection & Immunity

Biography

Biography

Marc Bonten earned his MD (1991) and PhD (“the role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia, 1994) at the Maastricht University Medical School, the Netherlands. He registered as internist in 2000, as infectious disease specialist in 2002 and as clinical microbiologist in 2008, all at the University Medical Center Utrecht, the Netherlands. From 2008 till March 2021 he was head of the Department of Medical Microbiology. Since 2003 he is head of the research group of Infectious Disease Epidemiology of the Julius Center of Health Sciences and Primary Care and professor of molecular epidemiology of infectious diseases. He has been a principal investigator in many large scale epidemiologic studies and investigator-initiated randomized trials of prevention and treatment of infectious diseases. His experience covers the full range of epidemiologic study designs including clinical trials, cohorts, case-control studies and mathematical modelling to study antibiotic resistance and infection prevention. Specific research interests include the epidemiology of antibiotic-resistant bacteria such as VRE, MRSA and MDR Enterobacteriaceae, selective decontamination in intensive care unit patients, prevention of ventilator-associated pneumonia, treatment of community-acquired pneumonia, and prevention and treatment of community-acquired pneumonia, including COVID-19.

He is scientific Director of the research theme "Tackling Antimicrobial Resistance" of the Netherlands Centre for One Health (NCOH; www.ncoh.nl). (2016-)

He is chairman of the strategic research program Infection & Immunity at the UMC Utrecht. (2017-)

Coordinator of the H2020-funded project ECRAID-Base (March 2021-) and Chief Executive Officer of the ECRAID foundation (Jan 2022-)

Member of the Koninklijke Nederlandse Academie voor Wetenschappen en Kunsten (Royal Academy of Sciences and Art) (April 2021-)

Side Activities

Advisory boards, DSMBs and steering committees 

Chair of international study steering committee EMBRACE study, Janssen Vaccines; payments to UMC Utrecht) (2017-);

Independent Data Monitoring Committee of the PSK008 and PSK009 studies on pneumococcal vaccination, Sanofi Pasteur (payments to UMC Utrecht) (2019-)

Advisory Board clinical development ensovibep for treatment COVID-19 (international), Novartis (payments to UMC Utrecht) (2022-)

Advisory Board clinical development for bactriophage therapy (international), Pherecytes (payments to Ecraid) (2022-)

Advisory Board pneumococcal vaccination (international), Merck Sharp & Dohme BV (payments to UMC Utrecht) (2020-)

Board member "stichting ter bevordering van onderzoek en onderwijs op het gebied van intensive care geneeskunde en infectieziekten". Unpaid. No recent activities. 

Activities ended

Advisory Board Covid-19 treatment (national), AstraZeneca (payments to UMC Utrecht) (2021);

Advisory Board pneumococcal vaccination (international), Pfizer (payments to UMC Utrecht) (2021);

Speaker fees

Takeda (Nov 2019) (payments to M. Bonten)

 

Expert panels

Netherlands Veterinary Medicines Institute (SDa) (2019-) (payments to UMC Utrecht).

Cluster Infectieziektenbestrijding from ZorgOnderzoek Nederland (2019-) (attendance fees to UMC Utrecht). 

Scientific Advisory Board of GARDP (Global Antibiotic Research & Development Platform (2020-) (no payments).

Advisory Panel Innovative Treatments COVID-19 of the Ministry of Health, Welfare and Sport (2020-) (attendance fees to UMC Utrecht).

Outbreak Management Team for COVID-19 (2020-) (attendance fees to UMC Utrecht)

 

Research activities: contract research

UMC Utrecht coordinates in the Netherlands the HERALD study; A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older een fase2/3 studie. Study sponsor: CureVac. Bonten is principal investigator for the Netherlands. (2020-) (no personal payments)

UMC Utrecht executes the EMPATHY study; a randomized double-blind placebo-controlled multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19. Study sponsor: Novartis & Molecular partners. Bonten is principal investigator for UMC Utrecht. (2021-) (no personal payments)

UMC Utrecht is a study site in the VAC31518COV2001 study; a phase 2 randomized double-blind placebo-controlled multicenter study of the COVID-19 vaccine from Janssen Vaccines. Study sponsor: Janssen Vaccines. Bonten is principal investigator for UMC Utrecht. (2020-) (no personal payments)

UMC Utrecht is a study site in the E.mbrace study; a phase 3 randomized double-blind placebo-controlled study of a 12-valent E. coli vaccine from Janssen Vaccines. Bonten is principal investigator for UMC Utrecht. (2022-) (no personal payments)

UMC Utrecht cordinates the PNEUMO study: an international observational study to quantify sero-type specific incidence of pneumococcal infections. Study sponsor: Merck. Bonten is principal investigator. (2018-) (no personal payments)

UMC Utrecht collaborates with Limmatech on exploring possibilities to study vaccination for Klebsiella infections. (2021-) (no personal payments)

Ecraid executes the open-label phase 2/3 clinical study to investigate safety and immunogenicity of a single VLA2100 booster vaccination in adult volunteers, after receipt of nationally rolled out mRNA COVID-19 vaccines and/or natural SARS-CoV2 infection. Study sponsor: Valneva Austria GmbH. Bonten is principal investigator. (2022-) (no personal payments)

Ecraid assists Spherecytes in the execution of PhagoDAIR I: A pilot, multicenter, randomized, non-comparative, double-blind study of phage therapy in patients with hip or knee prosthetic joint infection due to Staphylococcus aureus treated with DAIR and antibiotic therapy. (no personal payments)

UMC Utrecht executed the CAPiTA study and 3 related observational studies with PCV13 (2007-2014). Bonten performed until 2016 - on request of Pfizer - presentations on the results of these studies. Payments to UMC Utrecht. (no personal payments)

 

Research activities: public private partnerships (PPP) funded through the Innovative Medicine Initiative (IMI)

Bonten is, on behalf of UMC Utrecht, coordinator of COMBACTE-NET, COMBACTE-CARE, COMBACTE-MAGNET en COMBACTE-CDI) with the aim to improve efficiency of clinical evaluation of new antimicrobial treatments. Collaboration in this PPP is with AstraZeneca, Pfizer, GSK, Basilea, AiCuris, DaVolterra, Janssen, Sanofi, BioMerieux and MSD (www.combacte.com). (2013-) COMBACTE CDI ended in 2021. (no personal payments)

Bonten is, on behalf of UMC Utrecht, co-coordinator of the PPP VITAL in which the effects of aging on vaccine response is investigated. Collaboration in this PPP is with Pfizer, GSK, Janssen, Sanofi, BioMerieux en MSD (https://vital-imi.eu/). (2017-) (no personal payments)

Bonten is, on behalf of UMC Utrecht, scientific coordinator of the PPP PrIMAVera (Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance) in which the potential effects of monoclonal antibodies and vaccines on the epidemiology of antimicrobial resistance will be investigated. Collaboration in this PPP is with GSK and Janssen. (2021-) (no personal payments)

UMC Utrecht is partner in VALUE-Dx in which the effects of diagnostics in the treatment of respiratory tract infections is investigated. Collaboration in this PPP is with BioMerieux, Abbot, Janssen, BioRad en BD (https://vital-imi.eu/). Bonten co-leads the ADEQUATE study in which collaboration is with BioMerieux. (2019-) (no personal payments)

 

Fellowship and Awards

He is a VICI laureate (2006) from the Dutch Science Association, Principal Investigator of the CAPiTA study, coordinator of the EU-funded project R-GNOSIS, scientific coordinator of the IMI-funded consortiums COMBACTE-NET, COMBACTE-CARE and COMBACTE-MAGNET. He is member of the International Trial Steering Committee of the REMAP-CAP study, and coordinator of ECRAID-Base.  


In 2015 he received the ESCMID 2015 Award for Excellence in Clinical Microbiology and Infectious Diseases.

In 2017 he received a honorary fellowship of the Royal College of Physicians of Ireland, and was awarded the ESCMID fellowship.

In 2021 he was elected member of the Koninklijke Nederlandse Academi voor Wetenschappen.

Research Output (804)

Selective Decontamination of the Digestive Tract:An Answer at Last?

Bonten Marc 15 Nov 2022, In: JAMA - The Journal of The American Medical Association. 328 , p. 2310-2311 2 p.

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients:a randomised controlled trial

Chastre Jean, François Bruno, Bourgeois Marc, Komnos Apostolos, Ferrer Ricard, Rahav Galia, De Schryver Nicolas, Lepape Alain, Koksal Iftihar, Luyt Charles-Edouard, Sánchez-García Miguel, Torres Antoni, Eggimann Philippe, Koulenti Despoina, Holland Thomas L, Ali Omar, Shoemaker Kathryn, Ren Pin, Sauser Julien, Ruzin Alexey, Tabor David E, Akhgar Ahmad, Wu Yuling, Jiang Yu, DiGiandomenico Antonio, Colbert Susan, Vandamme Drieke, Coenjaerts Frank, Malhotra-Kumar Surbhi, Timbermont Leen, Oliver Antonio, Barraud Olivier, Bellamy Terramika, Bonten Marc, Goossens Herman, Reisner Colin, Esser Mark T, Jafri Hasan S, 15 Nov 2022, In: Critical care (London, England). 26

Air pollution from livestock farms and the oropharyngeal microbiome of COPD patients and controls

van Kersen Warner, Bossers Alex, de Steenhuijsen Piters Wouter A.A., de Rooij Myrna M.T., Bonten Marc, Fluit Ad C., Heederik Dick, Paganelli Fernanda L., Rogers Malbert, Viveen Marco, Bogaert Debby, Leavis Helen L., Smit Lidwien A.M. Nov 2022, In: Environment International. 169 , p. 1-9

The prevalence of persistent bacteraemia in patients with a non-staphylococcal infective endocarditis, a retrospective cohort study

van der Vaart Thomas W, Stuifzand Marjon, Boekholdt S Matthijs, Cramer Maarten J, Bonten Marc J M, Prins Jan M, van der Meer Jan T M 21 Aug 2022, In: International Journal of Cardiology. 367 , p. 49-54 6 p.

The 2021 Dutch Working Party on Antibiotic Policy (SWAB) guidelines for empirical antibacterial therapy of sepsis in adults

Sieswerda Elske, Bax Hannelore I, Hoogerwerf Jacobien J, de Boer Mark G J, Boermeester Marja, Bonten Marc J M, Dekker Douwe, van Wijk Roy Gerth, Juffermans Nicole P, Kuindersma Marnix, van der Linden Paul D, Melles Damian C, Pickkers Peter, Schouten Jeroen A, Rebel Jasper R, van Zanten Arthur R H, Prins Jan M, Wiersinga W Joost 11 Aug 2022, In: BMC Infectious Diseases. 22 , p. 1-16

PROPHETIC EU:Prospective Identification of Pneumonia in Hospitalized Patients in the Intensive Care Unit in European and United States Cohorts

Bergin Stephen P, Calvert Sara B, Farley John, Sun Jie-Lena, Chiswell Karen, Dieperink Willem, Kluytmans Jan, Lopez-Delgado Juan Carlos, Leon-Lopez Rafael, Zervos Marcus J, Kollef Marin H, Sims Matthew, Kabchi Badih A, Rubin Daniel, Santiago Jonas, Natarajan Mukil, Tenaerts Pamela, Fowler Vance G, Holland Thomas L, Bonten Marc J, Hullegie Sebastiaan J Jul 2022, In: Open forum infectious diseases. 9 , p. 1-10

Transmission of SARS-CoV-2 within households:a remote prospective cohort study in European countries

Verberk Janneke D M, de Hoog Marieke L A, Westerhof Ilse, van Goethem Sam, Lammens Christine, Ieven Greet, de Bruin Erwin, Eggink Dirk, Bielicki Julia A, Coenen Samuel, van Beek Janko, Bonten Marc J M, Goossens Herman, Bruijning-Verhagen Patricia C J L 28 May 2022, In: European Journal of Epidemiology. 37 , p. 549-561 13 p.

Transmission routes of antibiotic resistant bacteria:a systematic review

Godijk Noortje G, Bootsma Martin C J, Bonten Marc J M 20 May 2022, In: BMC Infectious Diseases. 22 , p. 1-15

Etiology of Myocardial Injury in Critically Ill Patients with Sepsis:A Cohort Study

Frencken Jos F, van Smeden Maarten, van de Groep Kirsten, Ong David S Y, Klein Klouwenberg Peter M C, Juffermans Nicole, Bonten Marc J M, van der Poll Tom, Cremer Olaf L, May 2022, In: Annals of the American Thoracic Society. 19 , p. 773-780 8 p.

Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial

Doesschate Thijs Ten, van der Vaart Thomas W, Debisarun Priya A, Taks Esther, Moorlag Simone J C F M, Paternotte Nienke, Boersma Wim G, Kuiper Vincent P, Roukens Anna H E, Rijnders Bart J A, Voss Andreas, Veerman Karin M, Kerckhoffs Angele P M, Oever Jaap Ten, van Crevel Reinout, van Nieuwkoop Cees, Lalmohamed Arief, van de Wijgert Janneke H H M, Netea Mihai G, Bonten Marc J M, van Werkhoven Cornelis W 28 Apr 2022, In: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 28 , p. 1278-1285 8 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet